Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen Dungan(The Ohio State University), Santiago Tofé Povedano, Thomas Först(Profil Institute for Metabolic Research), José Gerardo González‐González(Universidad Autónoma de Nuevo León), Charles Atisso(Eli Lilly (United States)), Whitney Sealls(Eli Lilly (United States)), Jessie L. Fahrbach(Eli Lilly (United States))
Cited by 487
Abstract
Related Papers
No related papers found
Powered by citation graph analysis